Cognitive impairment is a debilitating feature of psychiatric disorders such as schizophrenia, substance use disorders (SUD), depression and Alzheimer’s disease. There is a significant need for treatments targeting key cognitive deficits including working memory and behavioral flexibility, and the development of these therapeutics have the potential for broad clinical use in psychiatry. d-Govadine (d-GOV) is […]
Read More